Osteoarthritis Knee Pain
Quarterly Sales (Approved)
August 31,2020 (Est)
Amp Volatility Score
Catalyst Info & Data Links
TITLE: ZILRETTA® in Osteoarthritis Knee Pain - Quarterly Sales
WHAT IS THE CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
August 31, 2020 (Est)
08-2019 Commercial Metrics Overview
11-2019 Commercial Metrics Overview
03-2020 Commercial Metrics Overview
05-2020 Commercial Metrics Overview
07-2020 Commercial Metrics Overview
2015: An intra-articular, extended-release formulation of triamcinolone acetonide prolongs and amplifies analgesic effect in patients with osteoarthritis of the knee: a randomized clinical trial. J Bone Joint Surg Am. 2015; 97(11):877-88.
~15 million have osteoarthritis (OA) of the knee in U.S (learn more)
MECHANISM OF ACTION / RATIONALE
Triamcinolone acetonide is a corticosteroid with anti-inflammatory and immunomodulating properties. It binds to and activates the glucocorticoid receptor, leading to activation of anti-inflammatory transcription factors such as lipocortins and inhibition of inflammatory transduction pathways by blocking the release of arachidonic acid and preventing the synthesis of prostaglandins and leukotrienes.
source: FDA Label (section 12.1)
Updated by HC
#FLXN, #ZILRETTA, #triamcinolone_acetonide, #OA, #knee_pain
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post